-
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Friday, April 17, 2020 - 11:49am | 804Read More...Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...
-
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
Friday, January 18, 2019 - 9:15am | 1122Read More...Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation of fat in the liver of people who do not consume alcohol. NAFLD is a less serious condition, although non-alcoholic steatohepatitis, or NASH — a subset of NAFLD — is life-threatening, given its...
-
Raymond James: Gilead In NASH For The Long Haul
Thursday, December 20, 2018 - 9:43am | 381Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced a strategic collaboration Wednesday with Scholar Rock Holding Corp (NASDAQ: SRRK). Although not strictly a nonalcoholic steatohepatitis, or NASH, deal, the initiative could be a sign that “Gilead is in NASH for the long haul,” according to...
